Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease
Identifieur interne : 003E16 ( Main/Merge ); précédent : 003E15; suivant : 003E17Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease
Auteurs : O. Rascol [France] ; J. G. Nutt [États-Unis] ; O. Blin [France] ; C. G. Goetz [États-Unis] ; J. M. Trugman [États-Unis] ; C. Soubrouillard [France] ; J. H. Carter [États-Unis] ; L. J. Currie [États-Unis] ; N. Fabre [France] ; C. Thalamas [France] ; W. J. Giardina [États-Unis] ; S. Wright [États-Unis]Source :
- Archives of neurology : (Chicago) [ 0003-9942 ] ; 2001.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Background: Dyskinesias are a frequent adverse effect of long-term levodopa therapy. The relative contribution of dopamine D1 and D2 receptor function to the pathophysiology of levodopa-induced dyskinesias remains a matter of controversy. Objective: To establish whether a selective D1 dopamine agonist induces more or less dyskinesia than levodopa in primed dyskinetic patients with Parkinson disease. Methods: We studied ABT-431, the prodrug of a fully selective D1 agonist, in 20 subjects with advanced Parkinson disease and a fluctuating response to levodopa complicated by dyskinesias. Eight patients were studied in a double-blind, randomized design (French centers); 12, in an open, randomized design (US centers). We assessed and compared the antiparkinsonian (Unified Parkinsons Disease Rating Scale) and dyskinetic (response induced by an acute challenge of a suprathreshold dose of levodopa and by 4 different ascending doses (5, 10, 20, and 40 mg) of ABT-431 during the 6 hours after the challenge. Results: The separate analysis of the double-blind and open data led to the same findings, ie, the antiparkinsonian and dyskinetic responses induced by ABT-431 were dose related. At the most effective doses (20 and 40 mg), ABT-431 exhibited similar antiparkinsonian benefit and produced similar dyskinesias as levodopa. Conclusion: Dopamine D1 agonists can induce a full antiparkinsonian response but do not support previous hypotheses suggesting that D1 agonists are more or less likely to produce dyskinesias than levodopa.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001251
- to stream PascalFrancis, to step Curation: 000187
- to stream PascalFrancis, to step Checkpoint: 001060
Links to Exploration step
Pascal:01-0148533Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Induction by Dopamine D<sub>1</sub> receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J. G." last="Nutt">J. G. Nutt</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, Oregon Health Sciences University</s1><s2>Portland</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Portland</settlement><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre of Clinical Pharmacology and Experimental Therapeutics, Marseille University Hospital</s1><s2>Marseille</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C. G." last="Goetz">C. G. Goetz</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Section of Movement Disorders, Department of Neurological Sciences, Rush-Presbyterian-St Luke's Hospital</s1><s2>Chicago, Ill</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Chicago, Ill</wicri:noRegion></affiliation></author><author><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J. M." last="Trugman">J. M. Trugman</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Virginia Health Sciences Center</s1><s2>Charlottesville</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Charlottesville</wicri:noRegion></affiliation></author><author><name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C." last="Soubrouillard">C. Soubrouillard</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre of Clinical Pharmacology and Experimental Therapeutics, Marseille University Hospital</s1><s2>Marseille</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J. H." last="Carter">J. H. Carter</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, Oregon Health Sciences University</s1><s2>Portland</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Portland</settlement><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Currie, L J" sort="Currie, L J" uniqKey="Currie L" first="L. J." last="Currie">L. J. Currie</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Virginia Health Sciences Center</s1><s2>Charlottesville</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Charlottesville</wicri:noRegion></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Giardina, W J" sort="Giardina, W J" uniqKey="Giardina W" first="W. J." last="Giardina">W. J. Giardina</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Neurological and Urological Diseases Research, Abbott Laboratories</s1><s2>Abbott Park, Ill</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Abbott Park, Ill</wicri:noRegion></affiliation></author><author><name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S." last="Wright">S. Wright</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Neurological and Urological Diseases Research, Abbott Laboratories</s1><s2>Abbott Park, Ill</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Abbott Park, Ill</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">01-0148533</idno><date when="2001">2001</date><idno type="stanalyst">PASCAL 01-0148533 INIST</idno><idno type="RBID">Pascal:01-0148533</idno><idno type="wicri:Area/PascalFrancis/Corpus">001251</idno><idno type="wicri:Area/PascalFrancis/Curation">000187</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001060</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001060</idno><idno type="wicri:doubleKey">0003-9942:2001:Rascol O:induction:by:dopamine</idno><idno type="wicri:Area/Main/Merge">003E16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Induction by Dopamine D<sub>1</sub> receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J. G." last="Nutt">J. G. Nutt</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, Oregon Health Sciences University</s1><s2>Portland</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Portland</settlement><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre of Clinical Pharmacology and Experimental Therapeutics, Marseille University Hospital</s1><s2>Marseille</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C. G." last="Goetz">C. G. Goetz</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Section of Movement Disorders, Department of Neurological Sciences, Rush-Presbyterian-St Luke's Hospital</s1><s2>Chicago, Ill</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Chicago, Ill</wicri:noRegion></affiliation></author><author><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J. M." last="Trugman">J. M. Trugman</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Virginia Health Sciences Center</s1><s2>Charlottesville</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Charlottesville</wicri:noRegion></affiliation></author><author><name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C." last="Soubrouillard">C. Soubrouillard</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre of Clinical Pharmacology and Experimental Therapeutics, Marseille University Hospital</s1><s2>Marseille</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J. H." last="Carter">J. H. Carter</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, Oregon Health Sciences University</s1><s2>Portland</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Portland</settlement><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Currie, L J" sort="Currie, L J" uniqKey="Currie L" first="L. J." last="Currie">L. J. Currie</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Virginia Health Sciences Center</s1><s2>Charlottesville</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Charlottesville</wicri:noRegion></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Neurology and Pharmacology, Institut National de la Santé et de la Recherce Médicale U 455, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Giardina, W J" sort="Giardina, W J" uniqKey="Giardina W" first="W. J." last="Giardina">W. J. Giardina</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Neurological and Urological Diseases Research, Abbott Laboratories</s1><s2>Abbott Park, Ill</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Abbott Park, Ill</wicri:noRegion></affiliation></author><author><name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S." last="Wright">S. Wright</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Neurological and Urological Diseases Research, Abbott Laboratories</s1><s2>Abbott Park, Ill</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Abbott Park, Ill</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Archives of neurology : (Chicago)</title><title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title><idno type="ISSN">0003-9942</idno><imprint><date when="2001">2001</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Archives of neurology : (Chicago)</title><title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title><idno type="ISSN">0003-9942</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term><term>Chemotherapy</term><term>D1 Dopamine receptor</term><term>Dopamine agonist</term><term>Dyskinesia</term><term>Human</term><term>Parkinson disease</term><term>Pathophysiology</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Dyskinésie</term><term>Stimulant dopaminergique</term><term>Récepteur dopaminergique D1</term><term>Chimiothérapie</term><term>Physiopathologie</term><term>Homme</term><term>Antiparkinsonien</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Dyskinesias are a frequent adverse effect of long-term levodopa therapy. The relative contribution of dopamine D<sub>1</sub> and D<sub>2</sub> receptor function to the pathophysiology of levodopa-induced dyskinesias remains a matter of controversy. Objective: To establish whether a selective D<sub>1</sub> dopamine agonist induces more or less dyskinesia than levodopa in primed dyskinetic patients with Parkinson disease. Methods: We studied ABT-431, the prodrug of a fully selective D<sub>1</sub> agonist, in 20 subjects with advanced Parkinson disease and a fluctuating response to levodopa complicated by dyskinesias. Eight patients were studied in a double-blind, randomized design (French centers); 12, in an open, randomized design (US centers). We assessed and compared the antiparkinsonian (Unified Parkinsons Disease Rating Scale) and dyskinetic (response induced by an acute challenge of a suprathreshold dose of levodopa and by 4 different ascending doses (5, 10, 20, and 40 mg) of ABT-431 during the 6 hours after the challenge. Results: The separate analysis of the double-blind and open data led to the same findings, ie, the antiparkinsonian and dyskinetic responses induced by ABT-431 were dose related. At the most effective doses (20 and 40 mg), ABT-431 exhibited similar antiparkinsonian benefit and produced similar dyskinesias as levodopa. Conclusion: Dopamine D<sub>1</sub> agonists can induce a full antiparkinsonian response but do not support previous hypotheses suggesting that D<sub>1</sub> agonists are more or less likely to produce dyskinesias than levodopa.</div></front></TEI><affiliations><list><country><li>France</li><li>États-Unis</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>Oregon</li><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Marseille</li><li>Portland</li><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name></region><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C." last="Soubrouillard">C. Soubrouillard</name><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name></country><country name="États-Unis"><region name="Oregon"><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J. G." last="Nutt">J. G. Nutt</name></region><name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J. H." last="Carter">J. H. Carter</name><name sortKey="Currie, L J" sort="Currie, L J" uniqKey="Currie L" first="L. J." last="Currie">L. J. Currie</name><name sortKey="Giardina, W J" sort="Giardina, W J" uniqKey="Giardina W" first="W. J." last="Giardina">W. J. Giardina</name><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C. G." last="Goetz">C. G. Goetz</name><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J. M." last="Trugman">J. M. Trugman</name><name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S." last="Wright">S. Wright</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003E16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:01-0148533
|texte= Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease
}}
| This area was generated with Dilib version V0.6.29. |  |